Homeoprotein OTX1 and OTX2 involvement in rat myenteric neuron adaptation after DNBS-induced colitis.
Homeobox genes
Inflammation
Myenteric plexus
OTX1
OTX2
Plasticity
iNOS
nNOS
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
09
2019
accepted:
20
12
2019
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
26
2
2020
Statut:
epublish
Résumé
Inflammatory bowel diseases are associated with remodeling of neuronal circuitries within the enteric nervous system, occurring also at sites distant from the acute site of inflammation and underlying disturbed intestinal functions. Homeoproteins orthodenticle OTX1 and OTX2 are neuronal transcription factors participating to adaptation during inflammation and underlying tumor growth both in the central nervous system and in the periphery. In this study, we evaluated OTX1 and OTX2 expression in the rat small intestine and distal colon myenteric plexus after intrarectal dinitro-benzene sulfonic (DNBS) acid-induced colitis. OTX1 and OTX2 distribution was immunohistochemically investigated in longitudinal muscle myenteric plexus (LMMP)-whole mount preparations. mRNAs and protein levels of both OTX1 and OTX2 were evaluated by qRT-PCR and Western blotting in LMMPs. DNBS-treatment induced major gross morphology and histological alterations in the distal colon, while the number of myenteric neurons was significantly reduced both in the small intestine and colon. mRNA levels of the inflammatory markers, TNFα, pro-IL1β, IL6, HIF1α and VEGFα and myeloperoxidase activity raised in both regions. In both small intestine and colon, an anti-OTX1 antibody labeled a small percentage of myenteric neurons, and prevalently enteric glial cells, as evidenced by co-staining with the glial marker S100β. OTX2 immunoreactivity was present only in myenteric neurons and was highly co-localized with neuronal nitric oxide synthase. Both in the small intestine and distal colon, the number of OTX1- and OTX2-immunoreactive myenteric neurons significantly increased after DNBS treatment. In these conditions, OTX1 immunostaining was highly superimposable with inducible nitric oxide synthase in both regions. OTX1 and OTX2 mRNA and protein levels significantly enhanced in LMMP preparations of both regions after DNBS treatment. These data suggest that colitis up-regulates OTX1 and OTX2 in myenteric plexus both on site and distantly from the injury, potentially participating to inflammatory-related myenteric ganglia remodeling processes involving nitrergic transmission.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory bowel diseases are associated with remodeling of neuronal circuitries within the enteric nervous system, occurring also at sites distant from the acute site of inflammation and underlying disturbed intestinal functions. Homeoproteins orthodenticle OTX1 and OTX2 are neuronal transcription factors participating to adaptation during inflammation and underlying tumor growth both in the central nervous system and in the periphery. In this study, we evaluated OTX1 and OTX2 expression in the rat small intestine and distal colon myenteric plexus after intrarectal dinitro-benzene sulfonic (DNBS) acid-induced colitis.
METHODS
METHODS
OTX1 and OTX2 distribution was immunohistochemically investigated in longitudinal muscle myenteric plexus (LMMP)-whole mount preparations. mRNAs and protein levels of both OTX1 and OTX2 were evaluated by qRT-PCR and Western blotting in LMMPs.
RESULTS
RESULTS
DNBS-treatment induced major gross morphology and histological alterations in the distal colon, while the number of myenteric neurons was significantly reduced both in the small intestine and colon. mRNA levels of the inflammatory markers, TNFα, pro-IL1β, IL6, HIF1α and VEGFα and myeloperoxidase activity raised in both regions. In both small intestine and colon, an anti-OTX1 antibody labeled a small percentage of myenteric neurons, and prevalently enteric glial cells, as evidenced by co-staining with the glial marker S100β. OTX2 immunoreactivity was present only in myenteric neurons and was highly co-localized with neuronal nitric oxide synthase. Both in the small intestine and distal colon, the number of OTX1- and OTX2-immunoreactive myenteric neurons significantly increased after DNBS treatment. In these conditions, OTX1 immunostaining was highly superimposable with inducible nitric oxide synthase in both regions. OTX1 and OTX2 mRNA and protein levels significantly enhanced in LMMP preparations of both regions after DNBS treatment.
CONCLUSIONS
CONCLUSIONS
These data suggest that colitis up-regulates OTX1 and OTX2 in myenteric plexus both on site and distantly from the injury, potentially participating to inflammatory-related myenteric ganglia remodeling processes involving nitrergic transmission.
Identifiants
pubmed: 32095330
doi: 10.7717/peerj.8442
pii: 8442
pmc: PMC7024580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e8442Informations de copyright
© 2020 Bistoletti et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Biochem Biophys Res Commun. 2014 Jan 31;444(1):1-5
pubmed: 24388989
Neurosci Res. 2008 Apr;60(4):457-9
pubmed: 18294714
Purinergic Signal. 2018 Dec;14(4):409-421
pubmed: 30269308
Pharmacol Rev. 2013 Jan 08;65(1):90-104
pubmed: 23300132
J Histochem Cytochem. 2010 Jul;58(7):669-78
pubmed: 20354145
Int J Mol Sci. 2019 Mar 25;20(6):
pubmed: 30934533
Eur Cytokine Netw. 2016 Jun 1;27(2):41-53
pubmed: 27478078
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584
pubmed: 28743984
Nat Rev Gastroenterol Hepatol. 2017 May;14(5):269-278
pubmed: 28144028
Aging Cell. 2017 Feb;16(1):173-182
pubmed: 27660103
Front Pharmacol. 2016 Oct 04;7:341
pubmed: 27757083
PLoS One. 2019 Feb 22;14(2):e0212856
pubmed: 30794676
Cancer Res. 2005 Feb 1;65(3):919-24
pubmed: 15705891
Neural Plast. 2016;2016:7931693
pubmed: 26881132
Life Sci. 2006 Oct 19;79(21):2032-42
pubmed: 16904127
Neurogastroenterol Motil. 2011 Feb;23(2):e91-103
pubmed: 21159064
Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):611-27
pubmed: 25001973
Toxins (Basel). 2019 Jul 31;11(8):
pubmed: 31370176
Pharmacol Res. 2019 Nov;149:104464
pubmed: 31553934
J Anat. 2001 Jul-Aug;199(Pt 1-2):53-62
pubmed: 11523829
PLoS One. 2015 Oct 07;10(10):e0139697
pubmed: 26444681
Mediators Inflamm. 2013;2013:857380
pubmed: 24227910
Eur J Pharmacol. 2000 May 26;397(1):49-54
pubmed: 10844098
PLoS One. 2018 Aug 3;13(8):e0201760
pubmed: 30075006
Neurogastroenterol Motil. 2013 Feb;25(2):e114-26
pubmed: 23279126
J Neurosci. 2013 Jun 12;33(24):9890-904
pubmed: 23761884
Sci Rep. 2017 Dec 15;7(1):17644
pubmed: 29247178
Neurogastroenterol Motil. 2001 Aug;13(4):339-52
pubmed: 11576393
Molecules. 2019 Apr 19;24(8):
pubmed: 31010141
Viruses. 2018 Jul 11;10(7):
pubmed: 29997306
Oxid Med Cell Longev. 2017;2017:1502489
pubmed: 29209446
Br J Pharmacol. 2003 May;139(2):309-20
pubmed: 12770936
J Neurosci. 2006 May 31;26(22):5955-64
pubmed: 16738237
PLoS One. 2014 Nov 24;9(11):e113613
pubmed: 25419700
Eur J Pharmacol. 2015 Mar 5;750:123-31
pubmed: 25641749
Auton Neurosci. 2015 Sep;191:67-77
pubmed: 25953245
Neurogastroenterol Motil. 2005 Feb;17(1):4-15
pubmed: 15670258
Am J Physiol Gastrointest Liver Physiol. 2017 Apr 1;312(4):G374-G389
pubmed: 28154013
Genomics. 1994 Jul 1;22(1):41-5
pubmed: 7959790
Aging Cell. 2006 Jun;5(3):247-57
pubmed: 16842497
Cell Tissue Res. 2012 Aug;349(2):565-76
pubmed: 22688956
Aliment Pharmacol Ther. 2008 Apr;27(8):621-37
pubmed: 18221407
FEBS Lett. 2011 Jun 6;585(11):1573-8
pubmed: 21565195
Oncogene. 2011 Jul 7;30(27):3096-103
pubmed: 21478910
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Neuroinflammation. 2010 Jul 08;7:37
pubmed: 20615234
Am J Pathol. 2014 Dec;184(12):3405-14
pubmed: 25307345
J Pediatr Surg. 2007 Dec;42(12):2062-6
pubmed: 18082708